| Overview |
| bsm-70443M |
| Cyclophilin B Antibody |
| WB, IP, ICC |
| Clone M019 detects a 20 kDa* band corresponding to the molecular mass of cyclophilin B on SDS-PAGE immunoblots of human LNCaP, MeWo, MCF7, and MDA-MB-231 cell lysates, as well as full length recombinant cyclophilin B, but does not detect recombinant cyclophilin A. The antibody can be used for western blot, immunoprecipitation, protein ELISA, and immunocytochemistry. |
| Human |
| Specifications |
| Unconjugated |
| Mouse |
| Clone M019 was generated from a proprietary antigen related to cyclophilin B from the MCF7 breast cancer cell line. |
| Monoclonal |
| M019 |
| IgG1 |
| Purified by Protein G. |
| PBS + 1 mg/ml BSA, 0.05% NaN3 and 50% glycerol |
| Storage at -20°C is recommended, as aliquots may be taken without freeze/thawing due to presence of 50% glycerol. Stable for at least 1 year at -20°C. |
| Target |
| P23284 |
| Peptidyl-prolyl cis-trans isomerase B, PPIase B, CYP-S1, Cyclophilin B, Rotamase B, S-cyclophilin, SCYLP, PPIB, CYPB |
| Cyclophilins are a highly conserved family of peptidylprolyl cis-trans-isomerases (PPI) that are targets of the immunosuppressant drug cyclosporin A. These isomerases have been proposed to aid in protein folding. Cyclophilin B (PPIB) is an ER-localized chaperone protein that associates with type I procollagen, and facilitates procollagen sorting and transport through the secretory compartment. Mutations in the cyclophilin B gene lead to aberrant biosynthesis of type I procollagen, and osteogenesis imperfecta, a disorder characterized by bone fragility. Cyclophilin B has also been implicated as a marker in several cancers, including glioblastomas, neuroblastomas, and gastric cancers. In gastric cancer, Stat3 suppression of miR-520d-5p leads to upregulation of its downstream target cyclophilin B, and enables the growth and survival of these cancer cells. |
| Application Dilution |
| WB |
1:300-5000 |
| IP |
1-2ug |
| ICC |
1:100-500 |
Powered by Bioz